Faculty Opinions recommendation of Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.

2010 ◽  
Author(s):  
Sharma Prabhakar
Keyword(s):  
Angiotensin Ii ◽  
Insulin Signaling ◽  
Term Treatment ◽  
Zucker Rats ◽  
Angiotensin Ii Receptor Blocker ◽  
Adipocyte Size ◽  
Angiotensin Ii Receptor ◽  
Long Term Treatment ◽  
Obese Zucker Rats

Landscape of Combination Therapy – Which Way Forward? Proceedings of the Satellite Symposium Held at the ESH European Meeting on Hypertension and Cardiovascular Protection, 27 April 2012, London

2012 ◽  
Vol 8 (3) ◽  
pp. 192
Author(s):  
Patricia Fonseca ◽  
Anna F Dominiczak ◽  
Stephen Harrap ◽  
◽  
◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Combination Therapy ◽  
Enzyme Inhibitor ◽  
Synergistic Effects ◽  
Term Treatment ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Long Term Treatment

Early combination therapy is more effective for hypertension control in high-risk patients than monotherapy, and current guidelines recommend the use of either an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for first-line therapy in patients younger than 55 years. Recent evidence shows that ACEIs reduce mortality, whereas ARBs show no apparent benefit despite their blood pressure lowering action. However, it is important to consider which blood pressure parameters should be targeted given that different drugs have distinct effects on key parameters. Remarkably, a high percentage of hypertensive patients whose treatment has brought these parameters within target ranges still remain at high risk of cardiovascular disease due to additional risk factors. Combination therapy with synergistic effects on blood pressure and metabolic control should thus be considered for the long-term treatment of hypertensive patients with co-morbid conditions.

Long-term treatment with angiotensin II type 1 receptor antagonist, CV-11974, restores β-catenin mRNA expression in volume-overloaded rabbit hearts

2002 ◽  
Vol 17 (1) ◽  
pp. 36-41 ◽  
Author(s):  
Makoto Itoh ◽  
Y. Takeishi ◽  
Shigekazu Nakada ◽  
Takuya Miyamoto ◽  
Yuichi Tsunoda ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Receptor Antagonist ◽  
Mrna Expression ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats

Hypertension ◽  
2001 ◽  
Vol 38 (4) ◽  
pp. 884-890 ◽  
Author(s):  
Erik J. Henriksen ◽  
Stephan Jacob ◽  
Tyson R. Kinnick ◽  
Mary K. Teachey ◽  
Michael Krekler
Keyword(s):  
Insulin Resistance ◽  
Angiotensin Ii ◽  
Zucker Rats ◽  
Angiotensin Ii Receptor ◽  
Receptor Antagonism ◽  
Obese Zucker Rats
Sign in / Sign up

Export Citation Format

Share Document